(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Pick Your Favored pizza beating - 2Pat Finn, actor from 'The Middle,' dies at 60 after bladder cancer diagnosis
- 3Investigating Free Cell Phones: What You Really want to Be aware
- 4Kaiser Permanente affiliates to pay $556 million to resolve US claims alleging Medicare fraud
- 5Pick Your Favored kind of salad
- Renewables cover over 50% of German electricity consumption in Q1
- Top Music and Dance Celebration: Which One Gets You Going?
- Exclusive-Drugmakers raise US prices on 350 medicines despite pressure from Trump
- Famous Network programs in Europe and America
- Highlight Correlation of Microsoft Surface Book and Surface Genius Workstations for Determination
- Most loved Amusement Park Firecrackers Show: Which One Lights Up Your Evening?
- Addressing sleep apnea early might decrease chances of developing Parkinson's disease
- Luigi Mangione‘s lawyers say Bondi’s death penalty decision was tainted by conflict of interest
- 6 Vehicle Rental Administrations: Pick Your Ideal Ride
